Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study - PubMed F2G.

🔬 New study: Olorofim shows promise for patients with invasive fungal disease who have limited treatment options. The first antifungal in its class, it demonstrated good tolerability and encouraging outcomes.
Read more 👉 pubmed.ncbi.nlm.nih.gov/40541222/
#IFD #Olorofim #Antifungal

Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study Only a small number of antifungal therapies for invasive fungal disease (IFD) are currently available, and many pathogens are resistant to one or more…

New hope for hard-to-treat fungal infections: Phase 2b results show #Olorofim is effective and well-tolerated in patients with few or no treatment options.
Read in The Lancet Infectious Diseases 👉 www.sciencedirect.com/science/arti...
#IFD #Antifungals #ClinicalTrials